Protection against persistence of hepatitis C
Authors:
- Andrea CoxACAndrea Cox
- Donald R HooverDHDonald R Hoover
- Xiao-Hong WangXWXiao-Hong Wang
- Qing MaoQMQing Mao
- Stuart RaySRStuart Ray
- Steffanie A StrathdeeSSSteffanie A Strathdee
- David VlahovDVDavid Vlahov
- David L ThomasDTDavid L Thomas
- 1 April 2002
- journal article
- Published by Elsevier in The Lancet
- Vol. 359 (9316) , 1478-1483
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- The Prevalence of Hepatitis C Virus Infection in the United States, 1988 through 1994New England Journal of Medicine, 1999
- Persistence of Viremia and the Importance of Long–Term Follow–Up After Acute Hepatitis C InfectionHepatology, 1999
- Interferon Alfa-2b Alone or in Combination with Ribavirin as Initial Treatment for Chronic Hepatitis CNew England Journal of Medicine, 1998
- Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virusThe Lancet, 1998
- Universal Hepatitis B Vaccination in Taiwan and the Incidence of Hepatocellular Carcinoma in ChildrenNew England Journal of Medicine, 1997
- Clinical Outcomes after Transfusion-Associated Hepatitis CNew England Journal of Medicine, 1995
- Hepatitis C virus in multiple episodes of acute hepatitis in polytransfused thalassaemic childrenThe Lancet, 1994
- Lack of Protective Immunity Against Reinfection with Hepatitis C VirusScience, 1992
- Immunity in Hepatitis C InfectionThe Journal of Infectious Diseases, 1992
- Isolation of a cDNA cLone Derived from a Blood-Borne Non-A, Non-B Viral Hepatitis GenomeScience, 1989